NCT04686994View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

January 19, 2021

Study Completion Date

February 7, 2021

Conditions
Overweight and ObesityNAFLDHyperlipidemia
Interventions
DRUG

ASC 41

Oral tablets

DRUG

ASC 41 Placebo

Oral tablets

Trial Locations (1)

Unknown

Hunan provincial people's hospital, Changsha

Sponsors
All Listed Sponsors
collaborator

Hunan Provincial People's Hospital

OTHER

lead

Gannex Pharma Co., Ltd.

INDUSTRY

NCT04686994 - Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects | Biotech Hunter | Biotech Hunter